Simvastatin Reduces Capsular Fibrosis around Silicone Implants

Area of Science:

• Biomedical Engineering
• Radiotherapy Research
• Pharmacology

Background:

• Capsular fibrosis and contracture are common complications following radiotherapy in breast reconstruction.
• Current prevention strategies for radiation-induced capsular fibrosis are limited.
• Simvastatin has demonstrated antifibrotic properties in various experimental models.

Purpose of the Study:

• To investigate the efficacy of simvastatin in mitigating peri-implant fibrosis in a rat model after radiation exposure.
• To evaluate the impact of simvastatin on capsular tissue characteristics and gene expression.

Main Methods:

• Male Sprague-Dawley rats received silicone implants and targeted radiation (10 Gy).
• The experimental group was treated with simvastatin (15 mg/kg/day), while the control group received water.
• Capsules were analyzed histologically and via real-time PCR for gene expression at 12 weeks.

Main Results:

• Simvastatin treatment resulted in a reduced average capsular thickness (371.2 μm vs. 491.2 μm).
• A significantly lower fibrosis ratio was observed in the simvastatin group (32.33% vs. 58.44%, P < 0.001).
• Gene expression of connective tissue growth factor (CTGF) and transforming growth factor-β1 (TGF-β1) was significantly decreased with simvastatin treatment (P < 0.001).

Conclusions:

• Simvastatin effectively reduces radiation-induced capsular fibrosis and thickness around silicone implants in rats.
• The drug significantly downregulates key fibrotic markers, CTGF and TGF-β1.
• Simvastatin presents a promising therapeutic option for managing capsular fibrosis in breast reconstruction patients.